The centre will allow STA Pharmaceutical to introduce transition metal catalyst-screening technology to its existing small molecule process development and manufacturing platform.
The new state-of-the-art facility will allow STA to carry out rapid screening of metal catalysts, ligands, bases, acids, chemical resolving reagents and amide formation coupling reagents.
The screening kits will enable high-throughput screening of metal catalysts and ligands for C-C, C-N, C-O and C-S formation reactions, as well as many other types of reactions such as chemical resolution and amide formation.
The technology allows the STA team to more rapidly find the optimal catalysts using a parallel interactive testing approach.
A team of scientists specialised in this technology are currently being trained in the company’s Shanghai R&D centre and once the new centre becomes fully operational in early November, they will move to the Changzhou site.
